Home
Resources
Publications
SAR Optimization Studies on Modified Salicylamides as a Potential Treatment for Acute Myeloid Leukemia Through Inhibition of the CREB Pathway

SAR Optimization Studies on Modified Salicylamides as a Potential Treatment for Acute Myeloid Leukemia Through Inhibition of the CREB Pathway

Hee-Don Chae, Nick Cox, Samanta Capolicchio, Jae Wook Lee, Naoki Horikoshi, Sharon Kam, Andrew A Ng, Jeffrey Edwards, Tae-León Butler, Justin Chan, Yvonne Lee, Garrett Potter, Mark C Capece, Corey W Liu, etc.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2307-2315.

PMID: 31253529

Abstract:

Disruption of cyclic adenosine monophosphate response element binding protein (CREB) provides a potential new strategy to address acute leukemia, a disease associated with poor prognosis, and for which conventional treatment options often carry a significant risk of morbidity and mortality. We describe the structure-activity relationships (SAR) for a series of XX-650-23 derived from naphthol AS-E phosphate that disrupts binding and activation of CREB by the CREB-binding protein (CBP). Through the development of this series, we identified several salicylamides that are potent inhibitors of acute leukemia cell viability through inhibition of CREB-CBP interaction. Among them, a biphenyl salicylamide, compound 71, was identified as a potent inhibitor of CREB-CBP interaction with improved physicochemical properties relative to previously described derivatives of naphthol AS-E phosphate.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP18228176	Naphthol AS-E phosphate		18228-17-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: